EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy
Kang J, Ko A, Kil S, Mallen-St Clair J, Shin D, Wang M, Srivatsan E. EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. Biochimica Et Biophysica Acta (BBA) - Reviews On Cancer 2022, 1878: 188827. PMID: 36309124, DOI: 10.1016/j.bbcan.2022.188827.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCetuximabErbB ReceptorsHead and Neck NeoplasmsHumansImmunotherapyReceptor Protein-Tyrosine KinasesTumor MicroenvironmentConceptsEpidermal growth factor receptorReceptor tyrosine kinasesEGFR mAbsNeck cancerEGFR monoclonal antibody cetuximabEra of immunotherapyTreatment of HNCMonoclonal antibody cetuximabTyrosine kinase inhibitorsEGFR variant IIIGrowth factor receptorMetastatic HNCEGFR resistanceImmune cellsClinical trialsOnly FDAAntibody cetuximabGrowth factor ligandsSmall molecule inhibitorsVariant IIIMTOR pathwayCombinatorial treatmentEGFR overexpressionTumor microenvironmentImmunotherapy